Devika Proteins Ltd

Dharti Proteins Ltd has announced that its Board of Directors will convene on Wednesday, July 15, 2026. The primary agenda item is to consider and approve the Unaudited Standalone Financial Results for the first quarter ended June 30, 2026. The meeting will also include a review of the Limited Review Report associated with these financial results. Other matters may be discussed with the chair's permission.

Dharti Proteins Ltd has announced a change in its ISIN (INE248C01013 to INE248C01021) following a corporate action involving capital reduction and allotment of shares. This action was executed as per an approved resolution plan under CIRP. The entire shareholding of erstwhile promoters has been cancelled, existing public shareholders' holdings were proportionally reduced, and new equity shares were allotted to the new promoter group and secured financial creditors. The new ISIN is now active in CDSL and NSDL systems.

Dharti Proteins Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is effective from July 1, 2026, and will extend until 48 hours after the declaration of the unaudited financial results for the quarter ending June 30, 2026. The decision aligns with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. All directors, promoters, designated employees, and connected persons are advised not to trade during this period. The date for the board meeting to approve the financial results will be communicated separately.

Dharti Proteins Ltd has received listing approval from BSE Limited for 5,00,000 equity shares of ₹10 each. This allotment was made pursuant to an approved resolution plan by the NCLT, Ahmedabad Bench, dated November 18, 2025. The shares include 25,000 allotted due to capital reduction and 4,75,000 shares, of which 4,25,000 were allotted to the Successful Resolution Applicant (Promoter Group) and 50,000 to a Secured Financial Creditor on a preferential basis. The company is now processing corporate actions with NSDL and CDSL and will apply for trading approval soon.

Dharti Proteins Ltd. announced the approval of its audited standalone financial results for the quarter and year ended March 31, 2026, during a Board of Directors meeting held on May 29, 2026. The results, along with the Auditor's Report, have been submitted as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting also addressed the impact of the approved Resolution Plan, including restructuring of debts and equity.

Dharti Proteins Ltd's Board of Directors approved the audited standalone financial results for the quarter and year ended March 31, 2026, following a meeting held on May 29, 2026. The auditor, N.S. Nanavati & Co., issued an unmodified opinion on the financial results. The meeting, conducted via video conferencing, commenced at 03:00 P.M. and concluded at 03:30 P.M. The company has also accounted for various effects including waiver/extinguishment of liabilities, restructuring of debts, cancellation and issuance of equity shares, write-off of certain assets and infusion of funds by the Successful Resolution Applicant in accordance with the terms of the approved Resolution Plan.

Dharti Proteins Ltd has announced a Board of Directors meeting scheduled for May 29, 2026, to consider and approve the audited standalone financial results for the fourth quarter and year ended March 31, 2026. The board will also review the audit report and discuss any other matters with the chair's permission.

Dharti Proteins Ltd has released its Annual Report for the financial year 2024-25. The company underwent Corporate Insolvency Resolution Process (CIRP) and was revived under an approved Resolution Plan finalized on November 18, 2025. New management took over on December 19, 2025, focusing on stabilizing operations and compliance. The company addressed delays in compliance under Regulation 34 of SEBI Listing Regulations due to the CIRP period and has now completed the required filings.

Dharti Proteins Ltd. convened the 3rd meeting of its Monitoring Committee on April 27, 2026, at 04:50 P.M. via video conferencing. The meeting concluded at 05:18 P.M. The company has disclosed this information in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dharti Proteins Ltd has announced the closure of its trading window for all promoters, board members, officers, designated employees, and specified connected persons, in accordance with the SEBI (Prohibition of Insider Trading) Regulations 2015 and the company's Code of Internal Procedures and Conduct for Prevention of Insider Trading in Securities. The closure will begin on Wednesday, 01st April, 2026 and will remain in effect until 48 hours after the declaration of the Audited Financial Results for the quarter and year ending on 31st March, 2026. All designated persons of the company, including their immediate relatives and insiders, are advised not to trade in the securities of the company during this period.